Breaking News

Aeterna Zentaris Names CCO

By Gil Roth | November 1, 2013

Dinges joins to guide commercial direction

Jude Dinges has been named senior vice president, chief commercial officer of Aeterna Zentaris Inc. as the company reorients itself to become a specialty biopharma company. AZ plans to commercialize its pipeline and pursue in-licensing and acquisition opportunities. The company is in the process of bringing macimorelin acetate to market as the first approved oral product for evaluating growth hormone deficiency in adults.

Mr. Dinges began his career nearly 30 years ago as a professional sales representative at Bristol Laboratories and later at Merck & Co., where he was promoted to positions with increased responsibilities in training, sales, management, marketing, and market development. While at Merck, he helped launch Cozaar, Fosamax, Singulair, Maxalt, Vioxx, and Vytorin. Mr. Dinges joined Novartis Pharmaceuticals in 2006 and became the Respiratory & Infectious Disease Specialty Medicines director in 2008. In 2009, he joined Amgen as executive director of Region Sales, Bone Health Business Unit, helping launch Prolia.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks